Information Provided By:
Fly News Breaks for June 7, 2016
ALXN, BIIB
Jun 7, 2016 | 10:40 EDT
Goldman Sachs analyst Terence Flynn lowered his price target on Biogen (BIIB) to $267 from $285 after removing opicinumab estimates from the firm's model following news that the Phase 2 SYNERGY trial of the drug in multiple sclerosis failed to meet its primary and secondary endpoints. Biogen's failed study represents another setback to sector sentiment in light of Alexion's (ALXN) Soliris Phase 3 data yesterday, Flynn added. The firm keeps a Neutral rating on Biogen shares, which are down 11.7% to $255.89 in morning trading.
News For BIIB;ALXN From the Last 2 Days
BIIB
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BIIB
BIIB
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BIIB
BIIB
BIIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.